COVID-19 cases are rising in these states amid summer wave, CDC data shows
In its latest report, the CDC said the number of cases is now growing or likely growing in at least 26 states and Washington, D.C. COVID-related emergency room visits for young kids are also the highest they've been since March, according to the data.
CBS News chief medical correspondent Dr. Jon LaPook told "CBS Mornings" Monday this is typical of what we've come to understand about summer spikes in cases.
"We now know that there's a winter spike and then there's a summer spike," he said. "And every year, I just looked last night, the number of deaths, the number of hospitalizations, is gradually going down each season. So that's the good news."
But, people shouldn't ignore the increases, he added.
"If it strikes you, especially for the vulnerable, and we're talking about very young children under age of 4, the elderly, people who are immunocompromised — there are millions of people who are immunocompromised out there — they can really get sick," LaPook said.
The latest COVID variants, named Nimbus and Stratus, are "no more deadly" than previous variants, LaPook said.
Data on previous variants, like NB.1.8.1 from earlier this year, for example, also did not show more severe illness compared to previous variants. Symptoms were broadly similar to those seen in earlier strains, too, including respiratory issues such as cough and sore throat, as well as systemic issues like fever and fatigue.
"The vaccines that were made for this season do cover the current variants, so that's good news," LaPook said. "I think the bottom line here is: Don't be blasé. It's the summer, people have all sorts of things. Be careful."
While the CDC website still says the COVID-19 vaccine helps protect you from "severe illness, hospitalization and death," there have been some shifts in recommendations.
LaPook admits we're in a bit of an odd period right now because the CDC has different vaccine recommendations than many of the major health organizations and societies.
The American College of Obstetricians and Gynecologists, for example, says pregnant people should get vaccinated.
"Because the baby ... before they can get a shot, they're really relying on the mother's immunity — the mother has the antibodies, goes through the placenta, and then the baby has some protection," LaPook explained.
Health and Human Services Secretary Robert F. Kennedy Jr. "said it's now shared decision making," LaPook said. "So that means that go talk to your clinician about it, which is always a good idea, but it's a little bit of a different recommendation than just saying, 'go get it.'"
The CDC also now recommends "shared clinical decision-making" for giving healthy children the COVID-19 vaccine. While the agency currently recommends most adults aged 18 and older get a 2024-2025 COVID-19 vaccine, it says it's especially important if you're 65 and older, at high risk for severe COVID-19 or have never received a COVID-19 shot.
COVID-19 cases are growing in these states, according to the CDC:
The CDC says COVID-19 cases are likely growing in the following places:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
10 minutes ago
- Fast Company
Cannabis drinks are taking market share and Big Alcohol is fighting back
Top alcohol makers have been sitting on the sidelines of a cannabis beverage boom, watching brands in the fast-growing category like Cann and Wynk make deals with beer and booze distributors, and gain valuable space on liquor store shelves. Now some alcohol companies, seeing their sales falter, are laying the groundwork to potentially enter the lucrative but risky market, a dozen founders of cannabis brands, ingredients suppliers and drinks manufacturers told Reuters. Drinks containing THC, the mood-altering ingredient in marijuana, are restricted to licensed dispensaries in 24 U.S. states where recreational use of pot is legal. But small amounts of THC can also be extracted from hemp, a crop that's related to marijuana but is legal federally. Beverages containing THC derived from hemp can be sold in many liquor shops, convenience stores and supermarkets. That's where Big Alcohol sees opportunity, despite some companies having been burned by past cannabis investments. Corona brewer Constellation Brands has been internally researching hemp-based cannabis drinks to weigh its next steps, a source familiar with the company's thinking said. Absolut vodka distiller Pernod Ricard has met with Brez, maker of drinks with THC derived from hemp, as recently as last month to discuss a possible investment, Brez's founder Aaron Nosbisch said. 'They did not invest now but are circling,' Nosbisch said. Pernod declined to comment on the meeting. Constellation Brands said it does not comment on rumors and speculation. Alcohol makers are still suffering a hangover following America's pandemic drinking binge, when sales spiked as cash-flush consumers splurged on pricey bottles of liquor for their homes, and then rushed back to bars when lockdown restrictions lifted. Alcohol sales have been falling ever since as inflation and interest rates rose and wallets became stretched. The companies also now face growing warnings from public health authorities who say drinking even small amounts of alcohol is associated with at least seven types of cancer. Overall U.S. beer volumes fell nearly 6% through May of this year, according to the Beer Institute. Volumes of spirits and wine sold in the same time period have declined by 5.6% and 9%, respectively, according to the Wine & Spirits Wholesalers of America. In a sign of tumult in the industry, the CEO of the world's biggest alcohol maker, Diageo, stepped down last week as the company struggles to revive growth. But hemp-based drinks are expanding fast. The market for drinks infused with THC from hemp is projected to top $1 billion in sales this year, according to market research firm Euromonitor, and climb past $4 billion in 2028. Molson Coors CEO Gavin Hattersley told Reuters in January he'd be naive to say THC beverages aren't having an effect 'at least in a small way.' Tilray Brands, the fourth-largest U.S. craft brewer with brands including Montauk and Shock Top, is selling its new hemp-derived THC seltzers through its beer distributors such as United Distributors in Georgia, executives told Reuters in an interview. The company's THC drinks are for sale in 13 states. 'There's not a real leader that's taken ahold of the (market) so far, and that's what we look to do,' Tilray's CEO Irwin Simon told Reuters earlier this year. Others, including Heineken's Lagunitas brand and Pabst Blue Ribbon, the fifth-largest U.S. brewer, have lent their names to THC seltzers for sale in dispensaries in California. Lagunitas is looking to grow distribution of its THC seltzer, potentially using hemp, to other states, a representative from Cannacraft, its ingredient supplier, said. A spokesperson for Lagunitas said it has no immediate plans to expand, but monitors market development and looks for opportunities as consumer tastes and regulations change. Boston Beer, the maker of Sam Adams, is one of the brewers with the clearest path to eventually enter the U.S. cannabis drinks market although it has not provided a time frame for doing so. The company is already selling its Teapot brand of THC-infused tea in Canada where weed is legal, and in the last year tested a potential U.S. version made from THC derived from hemp. To test the reformulated product, a panel of trained sensory experts sampled Teapot with both THC from hemp and marijuana, and could not taste a difference, said the company's head of cannabis, Paul Weaver. 'This is a source of growth for our organization, flat out,' Weaver said. CAUTIOUS MOVES Big Alcohol is treading carefully in cannabis drinks because state and federal regulations have shifted, and could change again, said five executives at ingredients suppliers and THC beverage brands. California, which has legal weed, banned hemp-based drinks last year to try to prevent children from consuming them. Other states have introduced special taxes or restricted sales, ambiguity that has held alcohol companies back from entering the market. Sen. Mitch McConnell, who helped first legalize hemp in 2018 to support farmers in his home state of Kentucky, in July introduced a provision in a government spending bill that could ban intoxicating products using the plant. McConnell wrote in an op-ed published in the Louisville Courier Journal on July 17 that his efforts are aimed at keeping THC gummies that look like familiar candies out of the hands of children. He did not provide comment beyond the op-ed. Big brewers have been burned by past cannabis investments. In 2022, the biggest U.S. brewer Anheuser-Busch inBev exited a deal with Tilray to research cannabis drinks in Canada. The same year, Molson Coors shuttered its U.S. business selling beverages infused with CBD, a compound in marijuana and hemp that does not have psychoactive effects, citing an uncertain regulatory environment. Constellation Brands restructured its investment in Canadian cannabis company Canopy Growth last year after poor sales. Now, however, hemp-based THC drinks are sold widely. Beyond beer's declining sales, brewers face an additional squeeze from tariffs, which threaten to push up prices for imported drinks, and Hispanic consumers, who are staying home due to fears of U.S. immigration enforcement. HIGH MARGINS Liquor stores are embracing the buzzy beverages to boost their margins as the drinks, typically more expensive than a six-pack of beer, start to outsell other types of alcohol. Jon Halper, CEO of Minnesota liquor store chain Top Ten Liquors, told Reuters in June that THC beverages now make up 15% of his business after the company introduced them two years ago. By next year, they could grow to rival wine, currently in the mid twenty percent of his sales, he said. The drinks take shelf space mostly from beer because they are in coolers, Halper said. The margins on cannabis beverages are higher than those for beer and spirits, helping his firm offset softening alcohol sales. Charleston, South Carolina-based Southern Horizon Logistics, a sister company of Budweiser distributor Southern Crown Partners, is now selling more hemp-based drinks than wine and spirits, said Justin Ashby, the company's chief administrative officer. Ryan Moses, CEO of Nashville, Tennessee-based beer, wine and spirits distributor Best Brands, said that growth from THC-infused drinks has helped offset flat and declining alcohol sales. Instead of possible layoffs, Moses has been able to re-allocate employees to the new category. 'It could be as big as the other categories five to 10 years from now,' Moses said. Consumers like Josh Goldberg, 39, of Lindenhurst, New York, are also trading out beer and tequila for THC seltzers. Goldberg made the switch almost two years ago, and hasn't had a drink since. 'It replaces the physical act of drinking with drinking something else,' Goldberg said. Halper, the owner of Minnesota liquor stores, said the customers buying THC-infused drinks tend to skew female and over the age of 35.
Washington Post
12 minutes ago
- Washington Post
U.S. nuclear and health agencies hit in Microsoft SharePoint breach
The National Institutes of Health and the federal agency responsible for securing the nation's nuclear weapons were among the victims in a global breach of Microsoft server software over the weekend, according to agency officials and other people familiar with the matter. The NIH breach, which has not been previously reported, involved at least one Microsoft SharePoint server system, said Andrew Nixon, a spokesman for the Department of Health and Human Services, and its scope and severity are being investigated.
Forbes
12 minutes ago
- Forbes
InnovationRx: Sarepta Blinks In Showdown With FDA
In this week's edition of InnovationRx, we look at Sarepta's showdown with the FDA, Moderna's use of quantum computers, a new top drug regulator at the FDA, ARCH Venture's latest biotech company, and more. To get it in your inbox, subscribe here . Sarepta Therapeutics CEO Douglas Ingram Bloomberg Finance U sually when the FDA asks a drugmaker to halt distribution of a treatment, the company complies. Last week, in a remarkable showdown, Sarepta Therapeutics refused to stop distribution of Elevidys, its therapy for the muscle-wasting disease Duchenne muscular dystrophy as the FDA had requested. Then, in a remarkable reversal, on Monday Sarepta blinked and said that it would indeed pause all shipments of Elevidys by Tuesday evening. The latest twist in the saga followed a decision by Children's Hospital Los Angeles to halt use of the drug while it was facing regulatory uncertainty. Elevidys is a gene therapy for Duchenne, a particularly severe form of muscular dystrophy, which typically kills patients before they turn 30. The one-time intravenous infusion was first approved in 2023 in an unusual decision that was made unilaterally by Peter Marks, a top FDA official, despite misgivings of his staff. Last Friday evening, the FDA had requested that Cambridge, Mass.-based Sarepta voluntarily stop all shipments of the drug, citing the deaths of three patients who had taken Elevidys or a similar drug (that's in early-stage clinical trials) from liver failure. Later that evening, Sarepta responded that it would continue to ship Elevidys for patients who do not use wheelchairs (who are generally younger and healthier), citing its own analysis that there were no new safety problems in these patients. It had already voluntarily halted sales to patients who use wheelchairs. The face-off between Sarepta and the FDA comes at a time when investment in gene therapy has slowed, and as Sarepta itself has laid off hundreds of employees. Sarepta's stock is down nearly 40% since last Thursday's close. It's unclear how long the 'pause' might last. The company is working on an enhanced immune-suppressing protocol that could reduce liver toxicity, but a senior FDA official told Stat yesterday that the drug faces an 'arduous and treacherous path' back to the market. Whatever ultimately happens, the ongoing saga highlights the questions about what risks are acceptable for patients with diseases that are fatal at a young age and how the potential for treatment should be balanced against the possibility of death from the therapy itself. Moderna M essenger RNA (or mRNA) is a hugely promising technology for future vaccines and therapies, as was demonstrated during the COVID-19 pandemic. One of its major advantages is that it provides instructions for the body itself to manufacture the medicine it needs, rather than delivering it. But developing new treatments is challenging, Wade Davis, vice president of computational science at Moderna (best known for developing those COVID vaccines), told Forbes . That's in part because of the fragile nature of mRNA–its primary function is serving as a temporary set of instructions for cellular machinery, so it doesn't stick around long. But for the purposes of medicine, it needs to be optimized so that it's both durable enough to provide an efficacious dose, but still transient enough to minimize potential side effects. The potential combinations are mind boggling. For example, there are 10^623 different ways to combine nucleotides in mRNA to encode for the same protein as the company's COVID vaccine, Davis said. To put that in perspective, 'there's only 10^80 particles in the universe,' he said. 'The numbers just go crazy.' Conventional computers, even supercomputers using the best AI algorithms, struggle with this sort of problem, he said. For one, because mRNA is so fragile, there aren't a lot of known structures that an AI program could be trained on. And when it comes to optimization of structures, the numbers are so large that it's difficult to scale, forcing chemists to rely on rules of thumb and oversimplifying the data to try and find solutions. Moderna has found one solution: quantum computing. It recently partnered with IBM to use its quantum hardware to optimize mRNA structures. Quantum computers are uniquely suited to solving large scale optimization problems like this, because they can search and compute potential solutions in parallel. By contrast conventional computers have to calculate everything in sequence, which goes ever slower the bigger the problem gets. Using IBM's quantum computers, Moderna was able to predict a 60-nucleotide sequence of mRNA. The previous record was only eight. While that's still a long way from the sequence lengths, comprising thousands of nucleotides, that biotech companies will need, it shows a potential new way to find new mRNA therapies. More importantly, it could lead to breakthroughs that might have never been discovered with conventional approaches. With quantum algorithms, Davis said, 'you get into the space of possibilities in a different way than some of the classical approaches.' BIOTECH AND PHARMA CAR-T cell therapy has been a life-saving treatment for patients with cancers like leukemia or lymphoma, with many going into remission. But the therapy so far has been less successful on solid tumors, which comprise most cancers. Dispatch Bio aims to change that: The three year-old company emerged from stealth today with $216 million in funding led by Midas Lister Bob Nelsen's ARCH Venture Partners and the Parker Institute for Cancer Immunotherapy. One reason it's challenging to treat solid cancers with CAR-T therapy is that it's more difficult for the cells to identify their targets, Dispatch Bio CEO Sabah Oney told Forbes . To get around this, Dispatch has developed a viral vector that targets cancer cells and then 'tags' them with a protein that the T-cells can use to attack the cancer. The virus uses the cancer cells' own replication system to make copies of itself, making it difficult for the cancer to develop a resistance to it. Because this mechanism is different in healthy cells, the risk is lower that the therapy would attack them. So far, the Philadelphia-based company has tested its therapy in both human cells in the lab and in animals, Oney said. It plans to start clinical trials in 2026, but is still working out what indication it will go after first. 'Ultimately, we have plans to be able to scale this approach so we can get to millions and millions of patients because that's the broad potential of this platform,' he said. 'We can do lung cancer, breast cancer, colon cancer with the same drug.' Plus : AstraZeneca plans to invest $50 billion in U.S. drug development and manufacturing by 2030 as pharma companies look for ways to deal with Trump's tariffs. DIGITAL HEALTH AND AI Mental healthcare startup Slingshot AI launched an AI-powered chatbot to provide support for those dealing with mental health issues. It simultaneously raised $53 million in venture funding led by Forerunner Ventures and Radical Ventures, bringing total funding to $93 million, at an undisclosed valuation. The chatbot, called Ash, has been beta tested with more than 50,000 patients. Plus : Aidoc, which has developed FDA-cleared algorithms for use by radiologists, raised $150 million led by General Catalyst and Square Peg at an undisclosed valuation. PUBLIC HEALTH AND HOSPITALS The FDA has named George Tidmarsh, a pediatric oncologist and pharma company veteran, as its top drug regulator, director of its Center for Drug Evaluation and Research. He will replace Jacqueline Corrigan-Curay, who has been serving in the role in an acting capacity after the departure of former director Patrizia Cavazzoni in January. Tidmarsh has led teams that have developed seven FDA-approved drugs and has served as CEO of several pharmaceutical companies in addition to being an adjunct professor at the Stanford School of Medicine. He takes over as the FDA has faced substantial upheaval under HHS Secretary Robert F. Kennedy Jr. WHAT WE'RE READING How a push for increased organ donation led to people enduring rushed or premature attempts to remove their organs. Wellness startup Truemed, cofounded by RFK Jr. aide Calley Means, helps people buy Peloton bikes and $9,000 saunas with tax-free funds set aside for healthcare. Bankrupt hospital system Steward Health sued its former CEO claiming he conducted insider transactions that drained its assets and led to its collapse. AI companies, including OpenAI, Grok and others have stopped warning users that their chatbots aren't doctors. Life sciences investment firm Omega Funds has raised $647 million for its eighth fund. Researchers figured out a way to deliver a vaccine using dental floss, which has so far been successfully tested on mice. Former Citigroup chair Sandy Weill gave $100 million to harness AI for a West Coast cancer hub. MORE FROM FORBES Forbes Vibe Coding Turned This Swedish AI Unicorn Into The Fastest Growing Software Startup Ever By Iain Martin Forbes Why JPMorgan Is Hitting Fintechs With Stunning New Fees For Data Access By Jeff Kauflin Forbes Go Back To The Office, But Bring Your Own Snacks. Blame Congress. By Kelly Phillips Erb
